CAUTIONFEDGLP-1 CompoundingJun 11, 2026

FDA shortage: Liraglutide Injection (Injection) — Currently in Shortage

Liraglutide remains in shortage; compounding is still permitted.

What changed & why it matters

Med Spa Radar recorded an FDA drug-shortage update at the federal level, dated June 11, 2026, in the GLP-1 Compounding category, naming Liraglutide.

The FDA drug-shortage list is the primary switch for whether Liraglutide may be compounded: shortage status has been the main legal basis for compounded semaglutide and tirzepatide, so a change to it narrows or widens what a 503A/503B pharmacy may prepare — often on a short timeline.

Type
FDA Drug Shortages
Jurisdiction
Federal
Category
GLP-1 Compounding
Substance
Liraglutide
Recorded
June 11, 2026

What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.

What to do

Free weekly Brief

Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.

Members get the full “what to do” on every alert — in real time, for your states. Become a member →

FDA Drug Shortages · primary source ↗

Related alerts

Monitoring, not legal advice.